To contact us Click HERE
J&J Settles Suit Alleging Injury from Risperdal Use:
"Johnson & Johnson (JNJ) agreed to a last-minute settlement of a lawsuit claiming that a boy's use of its antipsychotic drug Risperdal caused abnormal breast growth.
The settlement--whose terms were confidential--averted a civil trial scheduled to begin Monday in which plaintiffs lawyers intended to summon J&J Chief Executive Alex Gorsky as a witness. Mr. Gorsky previously held leadership roles at the J&J division responsible for marketing Risperdal during the period when the boy's alleged injury occurred.
Robert C. Hilliard, an attorney for the plaintiff, told a judge in the Philadelphia Court of Common Pleas Monday "this case has reached a final resolution." He said the settlement amount was confidential.
An attorney for J&J declined to elaborate. A company spokeswoman couldn't immediately be reached. Before the settlement, J&J said in a statement the claim was without merit.
J&J disclosed in its annual report in February that it was facing about 420 product-liability claims and lawsuits related to use of Risperdal. The drug, which treats schizophrenia, bipolar mania and irritability associated with autism, has been linked to increased risk for various adverse events including weight gain and elevated blood sugar.
The lawsuit at the center of Monday's settlement alleged that a boy developed gynecomastia, or abnormal breast development in males, as a result of Risperdal use between 1999 and 2004, said his attorney, Stephen A. Sheller. The boy, now an adult, had his breasts removed surgically, Mr. Sheller said.
The lawsuit alleged that J&J didn't sufficiently warn of the risk of gynecomastia."
Hiç yorum yok:
Yorum Gönder